Advertisement

Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration—the future has begun

  • Justus G. Garweg
  • J. J. Zirpel
  • C. Gerhardt
  • Isabel B. Pfister
Letter to the Editor
  • 103 Downloads

Dear Editor,

We would like to thank Dan and Mihai Călugăru for their critical interest in our recently published work [1]. This gives us the opportunity to address the remarkable improvements that have been achieved by adopting ideal world outcomes in the therapy of exudative or wet age-related macular degeneration (AMD) using ranibizumab to the real world possibilities.

Ranibizumab was the first drug approved for the prevention of vision loss in wet AMD in 2006. The ophthalmological community believed that now a bright future had begun. Indeed, its approval revolutionized ophthalmology and opened the treatment floor for a group of vascular diseases affecting the macula that had been perceived widely untreatable by then. As we have meanwhile learned, beneficial anti-VEGF effects reach not only the macula, but eventually the entire retina [2].

Marina [3] and Anchor [4] were the first studies to show that severe vision loss and legal blindness were not any more an inevitable consequence...

Notes

Compliance with ethical standards

Conflict of interest

JGG acts as an advisor to diverse pharmaceutical companies and contributes to several clinical studies. Nevertheless, none of the authors have received direct or indirect financial support for this study or have a conflicting interest with the data that are presented in the report.

For this type of study formal consent is not required.

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Garweg JG, Zirpel JJ, Gerhardt C, Pfister IB (2018) The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol 256:823–831CrossRefPubMedGoogle Scholar
  2. 2.
    Ip MS, Zhang J, Ehrlich JS (2017) The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology 124:596–603CrossRefPubMedGoogle Scholar
  3. 3.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMedGoogle Scholar
  4. 4.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRefPubMedGoogle Scholar
  5. 5.
    Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627–637CrossRefPubMedGoogle Scholar
  6. 6.
    Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731–1739CrossRefPubMedGoogle Scholar
  7. 7.
    Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Quaggin SE (2012) Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122:3849–3851CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Garweg JG (2016) Makula-Atrophie bei feuchter altersabhängiger Makula- Degeneration – unausweichliche Folge der anti-VEGF-Therapie ? Ophthalmologe 113:1036–1045CrossRefPubMedGoogle Scholar
  10. 10.
    Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists’ Guidelines Committee (EURETINA) (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486–494CrossRefPubMedGoogle Scholar
  11. 11.
    Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, Sustain Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663–671CrossRefPubMedGoogle Scholar
  12. 12.
    Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:1751–1761CrossRefGoogle Scholar
  13. 13.
    Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299CrossRefPubMedGoogle Scholar
  14. 14.
    Garweg JG, Niderprim SA, Russ HM, Pfister IB (2017) Comparison of strategies of treatment with ranibizumab in newly-diagnosed cases of Neovascular age-related macular degeneration. J Ocul Pharmacol Ther 33:773–778CrossRefPubMedGoogle Scholar
  15. 15.
    Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, European Society of Retina Specialists (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144–1167CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunović H (2017) A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond). 31:26–44CrossRefPubMedGoogle Scholar
  17. 17.
    Lanzetta P, Loewenstein A, Vision Academy Steering Committee (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 255:1259–1273CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 29:721–731CrossRefGoogle Scholar
  19. 19.
    Garweg JG, Russ HM, Pfister IB (2017) Early response to ranibizumab is predictive of treatment demand after a therapeutic switch to aflibercept. Ophthalmology Retina 1:210–216CrossRefGoogle Scholar
  20. 20.
    Stewart MW (2015) Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? Or losing? J Clin Med. 4:1079–1101CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR, TREX-AMD Study Group (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRefPubMedGoogle Scholar
  22. 22.
    Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR, TREX-AMD Study Group (2018) Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol 102:460–464CrossRefPubMedGoogle Scholar
  23. 23.
    Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2016) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100:914–917 Though our study suggests superiority of the treat and extend regimen to PRN treatment in a 12-month period, this review demonstrates the need for randomised clinical trials to confirm our findings and to evaluate long-term efficacy outcomes with these regimens compared with monthly therapyCrossRefPubMedGoogle Scholar
  24. 24.
    Schlottmann PG, Alezzandrini AA, Zas M, Rodriguez FJ, Luna JD, Wu L (2017) New treatment modalities for Neovascular age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 6:514–519Google Scholar
  25. 25.
    Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, Barthelmes D, Gillies MC (2018) Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res pii S1350-9462(17):30105–30102Google Scholar
  26. 26.
    Ord LM, Wright J, DeAngelis MM, Feehan M (2016) Quality of life with macular degeneration is not as dark as it may seem: patients’ perceptions of the MacDQoL questionnaire. J Clin Med 4:1841–1852CrossRefGoogle Scholar
  27. 27.
    Cascella R, Strafella C, Caputo V, Errichiello V, Zampatti S, Milano F, Potenza S, Mauriello S, Novelli G, Ricci F, Cusumano A, Giardina E (2018) Towards the application of precision medicine in age-related macular degeneration. Prog Retin Eye Res 63:132–146CrossRefPubMedGoogle Scholar
  28. 28.
    Wei X, Zhang T, Yao Y, Zeng S, Li M, Xiang H, Zhao C, Cao G, Li M, Wan R, Yang P, Yang J (2018) Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser-induced CNV mouse model of neovascular AMD. Exp Eye Res 168:2–11CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Justus G. Garweg
    • 1
    • 2
  • J. J. Zirpel
    • 2
  • C. Gerhardt
    • 1
    • 2
  • Isabel B. Pfister
    • 1
    • 2
  1. 1.Swiss Eye Institute, Rotkreuz, and Berner Augenklinik am LindenhofspitalRotkreuzSwitzerland
  2. 2.University of BernBernSwitzerland

Personalised recommendations